Dr Craig Gedye (Calvary Mater Newcastle, Australia) discussed the KEYPAD trial (NCT03280667) at ASCO GU 2021 [1]. While some benefit is derived from treatment with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors, the prognosis for patients with unresectable or metastatic ccRCC remains poor, as the disease inevitably progresses. Cytokine immunotherapy, although highly toxic, has met with some success.
KEYPAD is a single-arm, multicentre, phase 2 trial aiming to investigate the activity and safety of combining denosumab with pembrolizumab in unresectable or metastatic ccRCC. The study will recruit 70 adults who will receive 200 mg pembrolizumab intravenously every 3 weeks (Q3W) combined with 120 mg denosumab subcutaneous on days 1, 8 and 22 and then Q3W until disease progression, toxicity, or participant withdrawal, up to a maximum of 2 years.
The primary completion date is scheduled for December 2022. The primary outcome measure will be the objective tumour response rate, as measured by Response Evaluation Criteria in Solid Tumours (RECIST) v1.1. Secondary outcome measures to be tracked are progression-free survival, disease control rate, time to objective tumour response, time to first skeletal-related event, frequency and severity of adverse events, and frequency of treatment delays and discontinuation due to toxicity.
Dr Gedye concluded that favourable outcomes may lead to a new standard of care and would offer new hope for those afflicted with unresectable or metastatic ccRCC.
- Gedye C. Denosumab and pembrolizumab in clear cell renal carcinoma (KEYPAD): A Phase 2 trial (ANZUP1601). Abstract TPS367, ASCO Genitourinary Cancers Symposium, 11–13 February 2021.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Prognosis of penile cancer associated with HPV status Next Article
Predictors of oral anti-cancer agent utilisation in renal cell carcinoma »
« Prognosis of penile cancer associated with HPV status Next Article
Predictors of oral anti-cancer agent utilisation in renal cell carcinoma »
Table of Contents: ASCO GU 2021
Featured articles
Prostate Cancer
Lu177 as a promising new therapy for metastatic prostate cancer
Role of prostate cancer genomics is evolving
Apalutamide prolongs progression-free survival in prostate cancer
Dose-intensified radiation therapy fails to provide better outcomes in prostate cancer
Intrinsic tumour biology may be predictive of treatment response in prostate cancer
Final TITAN trial results favour use of apalutamide
Penile Cancer
Prognosis of penile cancer associated with HPV status
Renal Cancer
Superior clinical outcomes and QoL with nivolumab plus cabozantinib in RCC
Lenvatinib plus pembrolizumab prolongs survival in renal cell carcinoma
Inflammatory markers may guide treatment decisions in metastatic renal cell cancer
Clinical trial exclusion criteria may lead to lack of evidence in real-world patients: how do the excluded fare?
Axitinib offers hope for improving renal cell cancer surgical outcomes
Cabozantinib as possible new first-line therapy in translocation renal cell carcinoma
Predictors of oral anti-cancer agent utilisation in renal cell carcinoma
Denosumab plus pembrolizumab in advanced clear cell renal cell carcinoma
Testicular Cancer
New prediction model for brain metastasis in germ cell tumours
Reduction in radiation exposure is possible in testicular seminoma surveillance
New therapeutic option for early metastatic seminoma
Urothelial Cancer
Poorer outcomes in bladder cancer predicted by race/ethnicity and gender
Enfortumab vedotin as a promising treatment option for bladder cancer: phase 3 results
Enfortumab vedotin as a promising treatment option for bladder cancer: phase 2 results
New standard of care recommended for patients with upper tract urothelial cancer
Signature DNA alterations in subtypes of bladder cancer
ACE inhibitors associated with superior responses in bladder cancer
Better allocation of research dollars needed
Better prediction of favourable responses to immune checkpoint inhibitors in mUC
Genitourinary Oncology
Researchers call for an overhaul of licensing and funding of anti-cancer drugs
Exploring a new strategy for metastatic germ cell tumours
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com